[Practice guidelines of the Spanish Society of Cardiology. Cardiac and heart-lung transplants].
Cardiac transplantation is the only therapy that is able to substantially modify the natural evolution of patients with severe heart failure, along with angiotensin converting enzyme inhibitors. Nevertheless, because of the limited number of donors, its impact is scarce compared to the magnitude of the problem. Up to the end of 1998, 48,541 orthotopic cardiac transplantations and about 2,510 heart and both lung transplantations have been registered throughout the world. In Spain 2,780 procedures have been performed in the last 15 years. The survival expectations for a transplanted patient is 75% after the first year and 60% the following 5 years. The average duration of the graft is 8 years and 6 months. Cardiac transplantation is indicated for young and middle-age patients with irreversible cardiac process in bad clinical condition, with no other possibility of medical or surgical management and with a limited life expectancy. The major debate when choosing this therapy appears with the critical patients, patients older than 65 years, and some patients with systemic diseases. The great demand of transplantation obliges the teams to enlarge the criteria for donors' acceptance. At the same time, the increase of the knowledge about the transmission of some infections, mainly viral, forces to review those criteria day-to-day. The use of different immunosuppressive strategies pursues the control of rejection. The most commonly used is the so-called triple therapy (cyclosporine-azathioprine and steroids). The use of antilymphocytic antibodies such as cytolytic induction treatment is not unanimously accepted. Some of the new immunosuppressive agents such as myphenolate-mofetil and tacrolimus seem to offer advantages mainly due to their greater potency. Since transplantation is a limited procedure, of which its practise has an effect on the whole health system of a country, a perfect planning and adequacy of the Centers is compulsory, as well as the setting-up of clear rules for the use of donors and priority of transplantation. Finally, the patient must be informed clearly and comprehensively at length of the risks, limitations and expectations of these complex procedures.
Alonso-Pulpón
L
L
Unidad de Insuficiencia Cardíaca y Trasplante Cardíaco, Hospital Puerta de Hierro, Madrid.
Almenar
L
L
Crespo
M G
MG
Silva
L
L
Segovia
J
J
Manito
N
N
Cuenca
J J
JJ
Juffé
A
A
Vallés
F
F
D001706:Biopsy / Q000592:standards; D002309:Cardiology / Q000592:standards*; D006084:Graft Rejection / Q000473:pathology; D016027:Heart Transplantation / Q000331:legislation & jurisprudence / Q000592:standards* / Q000706:statistics & numerical data; D016041:Heart-Lung Transplantation / Q000331:legislation & jurisprudence / Q000592:standards / Q000706:statistics & numerical data; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D018579:Patient Selection; D013030:Spain; D014019:Tissue Donors
D007166:Immunosuppressive Agents